Multiple Sulfatase Deficiency

Genetic MONDO:0010088 Pathograph 43 Lysosomal Storage Disease Sphingolipidosis Developmental Anomaly of Metabolic Origin

Multiple sulfatase deficiency is an ultra-rare autosomal recessive lysosomal storage disorder caused by biallelic pathogenic variants in SUMF1, which encodes formylglycine-generating enzyme. Defective FGE impairs the post-translational activation of cellular sulfatases, reducing multiple sulfatase activities and causing glycosaminoglycan and sulfatide storage with progressive neurodegeneration, ichthyosis, hepatosplenomegaly, ocular disease, hearing impairment, skeletal involvement, and coarse facial features.

Ask OpenScientist

Ask a research question about Multiple Sulfatase Deficiency. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
7
Pathophys.
1
Histopath.
31
Phenotypes
43
Pathograph
1
Genes
3
Treatments
3
Subtypes
9
References
1
Deep Research
👪

Inheritance

1
Autosomal recessive inheritance HP:0000007
Multiple sulfatase deficiency is inherited in an autosomal recessive manner and is caused by biallelic SUMF1 variants.
Autosomal recessive inheritance
Show evidence (2 references)
ORPHA:585 SUPPORT Other
"Autosomal recessive"
Orphanet lists autosomal recessive inheritance.
PMID:39789203 SUPPORT Human Clinical
"Disease-causing homozygous or compound heterozygous variants in SUMF1 result in MSD."
Human case-series background supports biallelic SUMF1 causation.
◆

Subtypes

3
Neonatal severe form
Severe form with antenatal or neonatal onset and multiple manifestations at birth; neonatal-onset cases have the lowest overall survival in systematic clinical review.
Show evidence (2 references)
ORPHA:585 SUPPORT Other
"neonatal (most severe form), infantile (most common form) or juvenile (rarest form)."
Orphanet lists the historical neonatal form and its severity.
PMID:32620537 SUPPORT Human Clinical
"cases with neonatal onset showed the lowest overall survival rate compared to late-infantile and juvenile onsets."
Systematic review supports worse prognosis in neonatal-onset MSD.
Infantile form
Historically the most common form, with onset in infancy and progressive multisystem disease.
Show evidence (1 reference)
ORPHA:585 SUPPORT Other
"neonatal (most severe form), infantile (most common form) or juvenile (rarest form)."
Orphanet identifies the infantile form as the most common historical form.
Juvenile attenuated form
Rarest and generally most attenuated historical form, with later onset and slower progression than neonatal disease.
Show evidence (1 reference)
ORPHA:585 SUPPORT Other
"neonatal (most severe form), infantile (most common form) or juvenile (rarest form)."
Orphanet identifies juvenile MSD as the rarest historical form.
⚙

Pathophysiology

7
SUMF1 Formylglycine-Generating Enzyme Deficiency
Pathogenic SUMF1 variants reduce formylglycine-generating enzyme stability or catalytic activity in the endoplasmic reticulum.
SUMF1 link
post-translational sulfatase activation link ↓ DECREASED
endoplasmic reticulum link
Downstream
Sulfatase Catalytic Activation Failure FGE deficiency prevents normal FGly-dependent activation of newly synthesized sulfatases.
Show evidence (3 references)
PMID:12757705 SUPPORT In Vitro
"C(alpha)-formylglycine (FGly) is the catalytic residue in the active site of eukaryotic sulfatases."
Cell/biochemical study establishes FGly as the active-site residue needed for sulfatase catalysis.
PMID:12757705 SUPPORT In Vitro
"We purified the FGly generating enzyme (FGE) and identified its gene and nine mutations in seven MSD patients."
Study identified FGE and MSD patient mutations.
PMID:32414121 SUPPORT Other
"SUMF1 mutations result in unstable, degradation-prone FGE that demonstrates reduced or absent catalytic activity, leading to decreased activity of all sulfatases."
Review summarizes the variant-level FGE stability and activity defect.
Sulfatase Catalytic Activation Failure
Failed FGE-dependent formylglycine generation lowers activity of multiple cellular sulfatases, including lysosomal sulfatases.
sulfatase activity link ↓ DECREASED
Downstream
Reduced multiple sulfatase activities Failed FGly-dependent activation produces simultaneous deficiency of multiple sulfatase activities.
Sulfated Substrate Lysosomal Storage Decreased sulfatase activities impair degradation of glycosaminoglycans and sulfatides.
Show evidence (3 references)
PMID:12757706 SUPPORT In Vitro
"In multiple sulfatase deficiency (MSD), a human inherited disorder, the activities of all sulfatases are impaired due to a defect in posttranslational modification."
Functional complementation paper directly states the shared sulfatase activity defect.
PMID:12757706 SUPPORT In Vitro
"Coexpression of SUMF1 with sulfatases results in a strikingly synergistic increase of enzymatic activity, indicating that SUMF1 is both an essential and a limiting factor for sulfatases."
SUMF1 coexpression increases sulfatase activity, supporting causality.
PMID:32414121 SUPPORT Other
"A complete loss of SUMF1 or FGE function results in decreased activity of all sulfatases rendering MSD a monogenetic disease"
Review supports broad sulfatase activity reduction from SUMF1/FGE loss.
Sulfated Substrate Lysosomal Storage
Reduced sulfatase activities cause lysosomal accumulation of glycosaminoglycans, sulfatides, and other sulfated substrates.
lysosome organization link ↕ DYSREGULATED
lysosome link
Downstream
Glycosaminoglycan and sulfatide accumulation
Mucopolysacchariduria Impaired degradation of sulfated glycosaminoglycans leads to urinary mucopolysaccharide excretion.
Neuroglial Lysosomal Dysfunction
Retinal and Auditory Degeneration
Skeletal and Joint Storage Manifestations
Hepatomegaly Visceral lysosomal storage contributes to liver enlargement.
Splenomegaly Visceral lysosomal storage contributes to spleen enlargement.
Ichthyosis Sulfatase deficiency and sulfated lipid/substrate storage produce the ichthyotic skin phenotype.
Coarse hair Hair changes are grouped with cutaneous storage manifestations.
Coarse facial features Mucopolysaccharidosis-like storage produces coarse craniofacial features.
Smooth philtrum Smooth philtrum is retained as a craniofacial manifestation with unresolved proximal mechanism.
Anteverted nares Anteverted nares is retained as a craniofacial manifestation with unresolved proximal mechanism.
Thick eyebrow Thick eyebrows are grouped with coarse craniofacial and hair manifestations.
Depressed nasal bridge Depressed nasal bridge is retained as a craniofacial manifestation with unresolved proximal mechanism.
Show evidence (2 references)
PMID:32414121 SUPPORT Other
"loss of sulfatase activity induces lysosomal storage of glycosaminoglycans and sulfatides and subsequent cellular pathology."
Review links sulfatase loss to lysosomal storage.
PMID:32620537 SUPPORT Human Clinical
"FGE deficiency results in widespread tissue accumulation of multiple sulphated substrates."
Systematic review supports tissue storage of sulfated substrates.
Neuroglial Lysosomal Dysfunction
Sulfatide and glycosaminoglycan storage in neurons and glia — particularly astrocytes — impairs lysosomal and autophagic function, compromising the cellular processes that maintain nervous-system homeostasis.
astrocyte link
autophagy link ↕ DYSREGULATED
lysosome link
Downstream
Neurodegeneration Astrocyte and neuroglial dysfunction drives progressive neuronal loss.
Show evidence (2 references)
PMID:32414121 SUPPORT Other
"This abnormal storage results in lysosomal dysfunction, impacting several cellular processes including autophagy"
Review supports lysosomal and autophagic dysfunction downstream of sulfated-substrate storage.
PMID:32414121 SUPPORT Model Organism
"Astrocyte specific knock-out of SUMF1 in a Cre/Lox MSD mouse model revealed lysosomal storage of substrates and autophagy substrates impairing astrocyte function."
Model-organism evidence connects SUMF1 loss to lysosomal storage and impaired astrocyte function.
Neurodegeneration
Neuroglial dysfunction produces progressive neuronal loss and central and peripheral nervous-system degeneration, manifesting as leukodystrophy-like disease, developmental impairment, regression, seizures, and peripheral nerve involvement.
brain link
Downstream
Hydrocephalus Hydrocephalus is connected through central nervous system involvement, but the proximal mechanism is not separately modeled.
Leukodystrophy
Microcephaly Microcephaly is modeled as a CNS growth/development manifestation of severe neurodevelopmental disease.
Macrocephaly Macrocephaly is modeled as a CNS growth or hydrocephalus-related manifestation with unresolved proximal mechanism.
Intellectual disability
Seizure
Global developmental delay
Neonatal hypotonia
Developmental regression
Abnormality of peripheral nerve conduction
Rapid neurologic deterioration
Show evidence (2 references)
PMID:32414121 SUPPORT Model Organism
"impairing astrocyte function. This led to neuronal loss thereby highlighting the importance of astrocyte dysfunction in the pathophysiology of MSD"
Model-organism evidence shows astrocyte dysfunction leads to neuronal loss in MSD.
PMID:32620537 SUPPORT Human Clinical
"MSD is an ultra-rare multisystem disorder with mainly neurologic, hearing and skin involvements."
Systematic clinical survey supports neurologic involvement as a main disease domain.
Retinal and Auditory Degeneration
MSD commonly affects sensory systems through retinal degeneration and sensorineural hearing impairment.
Downstream
Sensorineural hearing impairment
Visual impairment
Cataract Cataract is modeled as an ocular manifestation of MSD, with the proximal tissue mechanism not separately curated.
Optic atrophy
Abnormality of retinal pigmentation
Corneal opacity Corneal opacity is modeled as an ocular storage manifestation with unresolved proximal mechanism.
Show evidence (3 references)
PMID:36980153 SUPPORT Human Clinical
"In 50-75% of all MSD-affected patients, functional or structural ocular damage is likely."
Ophthalmology review supports common ocular damage.
PMID:36980153 SUPPORT Human Clinical
"The main pathology these patients present is a highly conspicuous tapetoretinal degeneration, similar to severe Retinitis pigmentosa, that leads to blindness at an early age."
Review identifies tapetoretinal degeneration as the main ocular pathology.
PMID:32620537 SUPPORT Human Clinical
"Leukodystrophy, neurosensorial hearing loss, and ichthyosis were the most frequent findings at diagnosis."
Systematic review supports hearing loss as a frequent diagnostic finding.
Skeletal and Joint Storage Manifestations
Mucopolysaccharidosis-like connective-tissue and skeletal storage pathology causes short stature, joint stiffness, and broad distal phalanges.
Downstream
Joint stiffness
Short stature Skeletal storage and dysplasia contribute to impaired linear growth.
Broad hallux phalanx
Broad thumb
Show evidence (2 references)
ORPHA:585 SUPPORT Other
"skeletal anomalies"
Orphanet definition includes skeletal anomalies among MSD manifestations.
PMID:32414121 SUPPORT Other
"Many individuals also have characteristic facial features consistent with MPS disorders, chondrodysplasia punctata, hepatosplenomegaly, and ichthyosis"
Review supports MPS-like skeletal/connective-tissue involvement.
✶

Histopathology

1
Pleomorphic lysosomal inclusions
Tissue pathology can show pleomorphic lysosomal inclusions in peripheral nerve Schwann cells and brain tissue, consistent with multisubstrate lysosomal storage.
Show evidence (1 reference)
PMID:32414121 SUPPORT Other
"Ultrastructural findings comprise pleomorphic lysosomal inclusions in Schwann cells detected in skin biopsies"
Review summarizes reported ultrastructural storage pathology.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Multiple Sulfatase Deficiency Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

31
Cardiovascular 1
Splenomegaly VERY_FREQUENT Splenomegaly (HP:0001744)
Show evidence (1 reference)
ORPHA:585 SUPPORT Other
"HP:0001744 | Splenomegaly | Very frequent (99-80%)"
Orphanet provides the phenotype association and frequency band.
Digestive 1
Hepatomegaly VERY_FREQUENT Hepatomegaly (HP:0002240)
Show evidence (1 reference)
ORPHA:585 SUPPORT Other
"HP:0002240 | Hepatomegaly | Very frequent (99-80%)"
Orphanet provides the phenotype association and frequency band.
Ear 1
Sensorineural hearing impairment FREQUENT Sensorineural hearing impairment (HP:0000407)
Show evidence (2 references)
ORPHA:585 SUPPORT Other
"HP:0000407 | Sensorineural hearing impairment | Frequent (79-30%)"
Orphanet provides the phenotype association and frequency band.
PMID:32620537 SUPPORT Human Clinical
"Leukodystrophy, neurosensorial hearing loss, and ichthyosis were the most frequent findings at diagnosis."
Systematic review supports hearing loss as a frequent finding at diagnosis.
Eye 5
Visual impairment VERY_FREQUENT Visual impairment (HP:0000505)
Show evidence (2 references)
ORPHA:585 SUPPORT Other
"HP:0000505 | Visual impairment | Very frequent (99-80%)"
Orphanet provides the phenotype association and frequency band.
PMID:36980153 SUPPORT Human Clinical
"In 50-75% of all MSD-affected patients, functional or structural ocular damage is likely."
Ophthalmology review supports common ocular involvement.
Cataract FREQUENT Cataract (HP:0000518)
Show evidence (1 reference)
ORPHA:585 SUPPORT Other
"HP:0000518 | Cataract | Frequent (79-30%)"
Orphanet provides the phenotype association and frequency band.
Optic atrophy FREQUENT Optic atrophy (HP:0000648)
Show evidence (1 reference)
ORPHA:585 SUPPORT Other
"HP:0000648 | Optic atrophy | Frequent (79-30%)"
Orphanet provides the phenotype association and frequency band.
Abnormality of retinal pigmentation FREQUENT Abnormal retinal pigmentation (HP:0007703)
Show evidence (2 references)
ORPHA:585 SUPPORT Other
"HP:0007703 | Abnormality of retinal pigmentation | Frequent (79-30%)"
Orphanet provides the phenotype association and frequency band.
PMID:36980153 SUPPORT Human Clinical
"The main pathology these patients present is a highly conspicuous tapetoretinal degeneration, similar to severe Retinitis pigmentosa, that leads to blindness at an early age."
Ophthalmology review supports retinal pigmentary degeneration as a major ocular manifestation.
Corneal opacity FREQUENT Corneal opacity (HP:0007957)
Show evidence (1 reference)
ORPHA:585 SUPPORT Other
"HP:0007957 | Corneal opacity | Frequent (79-30%)"
Orphanet provides the phenotype association and frequency band.
Head and Neck 5
Microcephaly OCCASIONAL Microcephaly (HP:0000252)
Show evidence (1 reference)
ORPHA:585 SUPPORT Other
"HP:0000252 | Microcephaly | Occasional (29-5%)"
Orphanet provides the phenotype association and frequency band.
Macrocephaly FREQUENT Macrocephaly (HP:0000256)
Show evidence (1 reference)
ORPHA:585 SUPPORT Other
"HP:0000256 | Macrocephaly | Frequent (79-30%)"
Orphanet provides the phenotype association and frequency band.
Coarse facial features FREQUENT Coarse facial features (HP:0000280)
Show evidence (1 reference)
ORPHA:585 SUPPORT Other
"HP:0000280 | Coarse facial features | Frequent (79-30%)"
Orphanet provides the phenotype association and frequency band.
Anteverted nares FREQUENT Anteverted nares (HP:0000463)
Show evidence (1 reference)
ORPHA:585 SUPPORT Other
"HP:0000463 | Anteverted nares | Frequent (79-30%)"
Orphanet provides the phenotype association and frequency band.
Depressed nasal bridge FREQUENT Depressed nasal bridge (HP:0005280)
Show evidence (1 reference)
ORPHA:585 SUPPORT Other
"HP:0005280 | Depressed nasal bridge | Frequent (79-30%)"
Orphanet provides the phenotype association and frequency band.
Integument 1
Ichthyosis VERY_FREQUENT Ichthyosis (HP:0008064)
Show evidence (2 references)
ORPHA:585 SUPPORT Other
"HP:0008064 | Ichthyosis | Very frequent (99-80%)"
Orphanet provides the phenotype association and frequency band.
PMID:32620537 SUPPORT Human Clinical
"Leukodystrophy, neurosensorial hearing loss, and ichthyosis were the most frequent findings at diagnosis."
Systematic review supports ichthyosis as a frequent diagnostic finding.
Limbs 1
Broad thumb FREQUENT Broad thumb (HP:0011304)
Show evidence (1 reference)
ORPHA:585 SUPPORT Other
"HP:0011304 | Broad thumb | Frequent (79-30%)"
Orphanet provides the phenotype association and frequency band.
Musculoskeletal 2
Neonatal hypotonia VERY_FREQUENT Neonatal hypotonia (HP:0001319)
Show evidence (1 reference)
ORPHA:585 SUPPORT Other
"HP:0001319 | Neonatal hypotonia | Very frequent (99-80%)"
Orphanet provides the phenotype association and frequency band.
Joint stiffness FREQUENT Joint stiffness (HP:0001387)
Show evidence (1 reference)
ORPHA:585 SUPPORT Other
"HP:0001387 | Joint stiffness | Frequent (79-30%)"
Orphanet provides the phenotype association and frequency band.
Nervous System 6
Hydrocephalus FREQUENT Hydrocephalus (HP:0000238)
Show evidence (1 reference)
ORPHA:585 SUPPORT Other
"HP:0000238 | Hydrocephalus | Frequent (79-30%)"
Orphanet provides the phenotype association and frequency band.
Leukodystrophy FREQUENT Leukodystrophy (HP:0002415)
Show evidence (1 reference)
PMID:32620537 SUPPORT Human Clinical
"Leukodystrophy, neurosensorial hearing loss, and ichthyosis were the most frequent findings at diagnosis."
Systematic review supports leukodystrophy as one of the most frequent findings at diagnosis.
Intellectual disability VERY_FREQUENT Intellectual disability (HP:0001249)
Show evidence (1 reference)
ORPHA:585 SUPPORT Other
"HP:0001249 | Intellectual disability | Very frequent (99-80%)"
Orphanet provides the phenotype association and frequency band.
Seizure FREQUENT Seizure (HP:0001250)
Show evidence (1 reference)
ORPHA:585 SUPPORT Other
"HP:0001250 | Seizure | Frequent (79-30%)"
Orphanet provides the phenotype association and frequency band.
Global developmental delay VERY_FREQUENT Global developmental delay (HP:0001263)
Show evidence (1 reference)
ORPHA:585 SUPPORT Other
"HP:0001263 | Global developmental delay | Very frequent (99-80%)"
Orphanet provides the phenotype association and frequency band.
Developmental regression VERY_FREQUENT Developmental regression (HP:0002376)
Show evidence (1 reference)
ORPHA:585 SUPPORT Other
"HP:0002376 | Developmental regression | Very frequent (99-80%)"
Orphanet provides the phenotype association and frequency band.
Growth 1
Short stature FREQUENT Short stature (HP:0004322)
Show evidence (1 reference)
ORPHA:585 SUPPORT Other
"HP:0004322 | Short stature | Frequent (79-30%)"
Orphanet provides the phenotype association and frequency band.
Other 7
Smooth philtrum FREQUENT Smooth philtrum (HP:0000319)
Show evidence (1 reference)
ORPHA:585 SUPPORT Other
"HP:0000319 | Smooth philtrum | Frequent (79-30%)"
Orphanet provides the phenotype association and frequency band.
Thick eyebrow FREQUENT Thick eyebrow (HP:0000574)
Show evidence (1 reference)
ORPHA:585 SUPPORT Other
"HP:0000574 | Thick eyebrow | Frequent (79-30%)"
Orphanet provides the phenotype association and frequency band.
Coarse hair FREQUENT Coarse hair (HP:0002208)
Show evidence (1 reference)
ORPHA:585 SUPPORT Other
"HP:0002208 | Coarse hair | Frequent (79-30%)"
Orphanet provides the phenotype association and frequency band.
Abnormality of peripheral nerve conduction VERY_FREQUENT Abnormality of peripheral nerve conduction (HP:0003134)
Show evidence (1 reference)
ORPHA:585 SUPPORT Other
"HP:0003134 | Abnormality of peripheral nerve conduction | Very frequent (99-80%)"
Orphanet provides the phenotype association and frequency band.
Rapid neurologic deterioration VERY_FREQUENT Rapid neurologic deterioration (HP:0007307)
Show evidence (1 reference)
ORPHA:585 SUPPORT Other
"HP:0007307 | Rapid neurologic deterioration | Very frequent (99-80%)"
Orphanet provides the phenotype association and frequency band.
Mucopolysacchariduria VERY_FREQUENT Mucopolysacchariduria (HP:0008155)
Show evidence (1 reference)
ORPHA:585 SUPPORT Other
"HP:0008155 | Mucopolysacchariduria | Very frequent (99-80%)"
Orphanet provides the phenotype association and frequency band.
Broad hallux phalanx FREQUENT Broad hallux phalanx (HP:0010059)
Show evidence (1 reference)
ORPHA:585 SUPPORT Other
"HP:0010059 | Broad hallux phalanx | Frequent (79-30%)"
Orphanet provides the phenotype association and frequency band.
🧬

Genetic Associations

1
SUMF1 (Biallelic pathogenic variants)
Show evidence (4 references)
ORPHA:585 SUPPORT Other
"SUMF1 | sulfatase modifying factor 1 | hgnc:20376 | Disease-causing germline mutation(s) in"
Orphanet lists SUMF1 as the disease-causing gene.
PMID:32414121 SUPPORT Other
"MSD is caused by impaired posttranslational activation of sulfatases through the formylglycine generating enzyme (FGE) encoded by the sulfatase modifying factor 1 (SUMF1) gene, which is mutated in MSD."
Review links SUMF1/FGE mutations to the biochemical defect.
PMID:32620537 SUPPORT Human Clinical
"Multiple Sulfatase Deficiency (MSD) is an inborn error of metabolism caused by pathogenic variants in the SUMF1 gene encoding the formylglycine-generating enzyme (FGE) that activates all known sulfatases."
Systematic clinical survey supports SUMF1 causation.
+ 1 more reference
💊

Treatments

3
Multidisciplinary palliative and supportive care
Action: palliative care MAXO:0000021
No curative therapy is established; management is individualized and multidisciplinary, addressing neurologic, respiratory, feeding, musculoskeletal, ocular, auditory, dermatologic, visceral, and family quality-of-life needs.
Show evidence (3 references)
PMID:32414121 SUPPORT Other
"No curative therapy is currently available for MSD."
Review states that established curative therapy is unavailable.
PMID:32414121 SUPPORT Other
"An expert-driven multidisciplinary approach with goal of a high quality-of-life for the affected individuals and also the care-givers should be the primary objective of care"
Review supports multidisciplinary quality-of-life-centered care.
PMID:29397290 SUPPORT Other
"we detail a comprehensive systems-based approach to the management of individuals with MSD, from the initial diagnostic evaluation to unique multisystem issues and potential management options."
Consensus statement supports systems-based complex management.
Hematopoietic cell transplantation
Action: bone marrow transplantation MAXO:0010030
Hematopoietic cell or bone marrow transplantation is investigational in MSD; a two-sibling attenuated-MSD case series reports correction of available biomarkers and possible slowing of disease progression, with longer follow-up needed.
Mechanism Target:
MODULATES Sulfated Substrate Lysosomal Storage — Donor-derived hematopoietic cells may provide lysosomal enzymatic cross-correction.
Show evidence (1 reference)
PMID:39789203 SUPPORT Human Clinical
"Two siblings with attenuated MSD underwent hematopoietic cell transplantation (HCT), evaluating the possibility of lysosomal enzymatic cross-correction from the donor cells."
Human case series states the proposed cross-correction rationale for HCT.
Show evidence (2 references)
PMID:39789203 SUPPORT Human Clinical
"There is evidence of correction of currently available biomarkers within 3 months post-HCT."
Case series supports biochemical correction after HCT.
PMID:39789203 SUPPORT Human Clinical
"These data suggest biochemical benefits post-transplant along with slowing of disease progression."
Case series supports possible clinical benefit while acknowledging need for longer follow-up.
AAV9-SUMF1 gene replacement therapy
Action: gene therapy MAXO:0001001
AAV9/SUMF1 gene replacement is a preclinical strategy designed to supply functional SUMF1 and restore sulfatase activity; evidence is currently from mouse and rat preclinical studies rather than clinical use.
Mechanism Target:
RESTORES SUMF1 Formylglycine-Generating Enzyme Deficiency — Gene replacement delivers functional SUMF1 coding sequence.
Show evidence (1 reference)
PMID:39870870 SUPPORT Model Organism
"We engineered a viral vector (AAV9/SUMF1) to deliver working copies of the SUMF1 gene and tested the vector in Sumf1 knock out mice"
Preclinical study describes AAV9/SUMF1 gene delivery in a mouse model.
RESTORES Sulfatase Catalytic Activation Failure — Functional SUMF1 restores FGE-dependent sulfatase activation.
Show evidence (1 reference)
PMID:39870870 SUPPORT Model Organism
"One-year post treatment, tissues show increased sulfatase activity, indicating functional SUMF1."
Preclinical study reports increased sulfatase activity after AAV9/SUMF1 treatment.
Show evidence (2 references)
PMID:39870870 SUPPORT Model Organism
"treatment of neonates extends survival up to 1-year post-injection."
Mouse study supports survival extension after neonatal AAV9/SUMF1 treatment.
PMID:39870870 SUPPORT Model Organism
"The treated mice show wide distribution of the SUMF1 gene, no signs of toxicity or neuropathy, improved vision and cardiac function, and no behavioral deficits."
Preclinical study supports broad distribution and phenotypic improvements.
🔬

Biochemical Markers

2
Reduced multiple sulfatase activities (Deficient)
Show evidence (2 references)
PMID:32414121 SUPPORT Other
"Historically, the clinical diagnosis of MSD was confirmed by measuring simultaneous deficiency of more than one sulfatase activity in patient leukocytes or fibroblasts."
Review supports simultaneous low sulfatase activity as a diagnostic biochemical finding.
PMID:29397290 SUPPORT Other
"When FGE is absent or insufficient, all 17 known human sulfatases are affected"
Consensus statement supports broad sulfatase involvement.
Glycosaminoglycan and sulfatide accumulation (Positive)
Show evidence (2 references)
PMID:32414121 SUPPORT Other
"loss of sulfatase activity induces lysosomal storage of glycosaminoglycans and sulfatides and subsequent cellular pathology."
Review supports storage of glycosaminoglycans and sulfatides.
PMID:32620537 SUPPORT Human Clinical
"FGE deficiency results in widespread tissue accumulation of multiple sulphated substrates."
Systematic review supports widespread accumulation of sulfated substrates.
{ }

Source YAML

click to show 
name: Multiple Sulfatase Deficiency
creation_date: "2026-05-06T22:35:33Z"
updated_date: "2026-05-07T03:30:08Z"
category: Genetic
parents:
- Lysosomal Storage Disease
- Sphingolipidosis
- Developmental Anomaly of Metabolic Origin
synonyms:
- MSD
- Austin disease
- Mucosulfatidosis
description: >-
  Multiple sulfatase deficiency is an ultra-rare autosomal recessive lysosomal
  storage disorder caused by biallelic pathogenic variants in SUMF1, which
  encodes formylglycine-generating enzyme. Defective FGE impairs the
  post-translational activation of cellular sulfatases, reducing multiple
  sulfatase activities and causing glycosaminoglycan and sulfatide storage with
  progressive neurodegeneration, ichthyosis, hepatosplenomegaly, ocular disease,
  hearing impairment, skeletal involvement, and coarse facial features.
disease_term:
  preferred_term: multiple sulfatase deficiency
  term:
    id: MONDO:0010088
    label: mucosulfatidosis
references:
- reference: ORPHA:585
  title: Multiple sulfatase deficiency
  found_in:
  - Multiple_Sulfatase_Deficiency-deep-research-fallback.md
  findings:
  - statement: >-
      Orphanet defines multiple sulfatase deficiency as a rare lysosomal
      disease combining features of several sulfatase deficiencies, with severe
      to attenuated neonatal, infantile, and juvenile forms.
    supporting_text: >-
      A rare lysosomal disease characterized by a clinical phenotype that
      combines the features of different sulfatase deficiencies (whether
      lysosomal or not).
- reference: PMID:32414121
  title: "Multiple Sulfatase Deficiency: A Disease Comprising Mucopolysaccharidosis, Sphingolipidosis, and More Caused by a Defect in Posttranslational Modification."
  found_in:
  - Multiple_Sulfatase_Deficiency-deep-research-fallback.md
  findings:
  - statement: >-
      Review evidence supports SUMF1/FGE deficiency, impaired sulfatase
      post-translational activation, decreased sulfatase activity, lysosomal
      glycosaminoglycan and sulfatide storage, diagnosis by sulfatase activity
      and SUMF1 testing, and lack of curative therapy.
    supporting_text: >-
      MSD is caused by impaired posttranslational activation of sulfatases
      through the formylglycine generating enzyme (FGE) encoded by the sulfatase
      modifying factor 1 (SUMF1) gene.
- reference: PMID:32620537
  title: A systematic cross-sectional survey of multiple sulfatase deficiency.
  found_in:
  - Multiple_Sulfatase_Deficiency-deep-research-fallback.md
  findings:
  - statement: >-
      A systematic review of 80 published MSD cases supports SUMF1 causation,
      widespread sulphated substrate accumulation, common leukodystrophy,
      hearing loss, ichthyosis, prevalence estimates, and worse survival in
      neonatal-onset disease.
    supporting_text: >-
      Through a systematic analysis of published cases, we retrieved 80 MSD
      cases and reviewed the disease clinical, biochemical, and genetic
      findings.
- reference: PMID:12757705
  title: Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C(alpha)-formylglycine generating enzyme.
  found_in:
  - Multiple_Sulfatase_Deficiency-deep-research-fallback.md
  findings:
  - statement: >-
      The original FGE discovery paper identified FGE/SUMF1 and MSD patient
      mutations, showed FGly formation as the common sulfatase activation step,
      and restored sulfatase activity in patient fibroblasts by FGE cDNA.
    supporting_text: >-
      We purified the FGly generating enzyme (FGE) and identified its gene and
      nine mutations in seven MSD patients.
- reference: PMID:12757706
  title: The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases.
  found_in:
  - Multiple_Sulfatase_Deficiency-deep-research-fallback.md
  findings:
  - statement: >-
      Functional complementation identified the MSD gene, rescued patient-cell
      sulfatase deficiency, and showed SUMF1 is essential and limiting for
      sulfatase activity.
    supporting_text: >-
      Coexpression of SUMF1 with sulfatases results in a strikingly synergistic
      increase of enzymatic activity, indicating that SUMF1 is both an essential
      and a limiting factor for sulfatases.
- reference: PMID:29397290
  title: "Complex care of individuals with multiple sulfatase deficiency: Clinical cases and consensus statement."
  found_in:
  - Multiple_Sulfatase_Deficiency-deep-research-fallback.md
  findings:
  - statement: >-
      Consensus evidence supports the multisystem clinical phenotype and a
      systems-based complex-care approach for diagnostic evaluation and
      management.
    supporting_text: >-
      we detail a comprehensive systems-based approach to the management of
      individuals with MSD, from the initial diagnostic evaluation to unique
      multisystem issues and potential management options.
- reference: PMID:36980153
  title: "Multiple Sulfatase Deficiency from an Ophthalmologist's Perspective-Case Report and Literature Review."
  found_in:
  - Multiple_Sulfatase_Deficiency-deep-research-fallback.md
  findings:
  - statement: >-
      Ophthalmology-focused review supports frequent ocular involvement,
      tapetoretinal degeneration, and progressive visual loss in MSD.
    supporting_text: >-
      In 50-75% of all MSD-affected patients, functional or structural ocular
      damage is likely.
- reference: PMID:39789203
  title: "Bone marrow transplantation reverses metabolic alterations in multiple sulfatase deficiency: a case series."
  found_in:
  - Multiple_Sulfatase_Deficiency-deep-research-fallback.md
  findings:
  - statement: >-
      A 2025 human case series reports biochemical correction and possible
      slowing of progression after hematopoietic cell transplantation in two
      siblings with attenuated MSD.
    supporting_text: >-
      These data suggest biochemical benefits post-transplant along with
      slowing of disease progression.
- reference: PMID:39870870
  title: Preclinical use of a clinically-relevant scAAV9/SUMF1 vector for the treatment of multiple sulfatase deficiency.
  found_in:
  - Multiple_Sulfatase_Deficiency-deep-research-fallback.md
  findings:
  - statement: >-
      A 2025 preclinical study supports AAV9/SUMF1 gene replacement in a mouse
      model, with survival extension, improved symptoms, and increased sulfatase
      activity.
    supporting_text: >-
      These preclinical studies highlight the potential of our AAV9/SUMF1
      vector, the design of which is directly translatable for clinical use, as
      a gene replacement therapy for MSD patients.
has_subtypes:
- name: Neonatal
  display_name: Neonatal severe form
  description: >-
    Severe form with antenatal or neonatal onset and multiple manifestations at
    birth; neonatal-onset cases have the lowest overall survival in systematic
    clinical review.
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "neonatal (most severe form), infantile (most common form) or juvenile (rarest form)."
    explanation: Orphanet lists the historical neonatal form and its severity.
  - reference: PMID:32620537
    reference_title: A systematic cross-sectional survey of multiple sulfatase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cases with neonatal onset showed the lowest overall survival rate compared to late-infantile and juvenile onsets."
    explanation: Systematic review supports worse prognosis in neonatal-onset MSD.
- name: Infantile
  display_name: Infantile form
  description: >-
    Historically the most common form, with onset in infancy and progressive
    multisystem disease.
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "neonatal (most severe form), infantile (most common form) or juvenile (rarest form)."
    explanation: Orphanet identifies the infantile form as the most common historical form.
- name: Juvenile
  display_name: Juvenile attenuated form
  description: >-
    Rarest and generally most attenuated historical form, with later onset and
    slower progression than neonatal disease.
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "neonatal (most severe form), infantile (most common form) or juvenile (rarest form)."
    explanation: Orphanet identifies juvenile MSD as the rarest historical form.
prevalence:
- population: Worldwide
  percentage: 1-9 per 1,000,000
  notes: >-
    Orphanet reports worldwide point prevalence in the 1-9 per million range;
    a systematic case survey estimated approximately 1 in 2,000,000.
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-9 / 1 000 000 | Worldwide | Point prevalence | PMID:33144036"
    explanation: Orphanet reports worldwide point prevalence.
  - reference: PMID:32620537
    reference_title: A systematic cross-sectional survey of multiple sulfatase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the disease prevalence was approximately 1/2,000,000."
    explanation: Systematic review provides an independent prevalence estimate.
progression:
- phase: Progressive multisystem neurodegenerative lysosomal storage disease
  notes: >-
    MSD usually presents in early childhood with systemic and neurologic
    manifestations, followed by progressive loss of motor, speech, hearing, and
    vision skills. Earlier onset is associated with more severe disease.
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Infancy"
    explanation: Orphanet lists infancy as one age-of-onset category.
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Neonatal"
    explanation: Orphanet lists neonatal onset for severe MSD.
  - reference: PMID:32414121
    reference_title: 'Multiple Sulfatase Deficiency: A Disease Comprising Mucopolysaccharidosis, Sphingolipidosis, and More Caused by a Defect in Posttranslational Modification.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MSD is a complex disease because it combines symptoms of single sulfatase deficiencies. It is a progressive, systemic, neurodegenerative disorder of early childhood."
    explanation: Review summarizes the progressive systemic neurodegenerative course.
  - reference: PMID:32414121
    reference_title: 'Multiple Sulfatase Deficiency: A Disease Comprising Mucopolysaccharidosis, Sphingolipidosis, and More Caused by a Defect in Posttranslational Modification.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The majority of individuals with MSD present with systemic features and psychomotor retardation followed by loss of motor skills, speech, hearing, and vision."
    explanation: Review describes progressive loss of acquired abilities.
inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    Multiple sulfatase deficiency is inherited in an autosomal recessive manner
    and is caused by biallelic SUMF1 variants.
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Autosomal recessive"
    explanation: Orphanet lists autosomal recessive inheritance.
  - reference: PMID:39789203
    reference_title: 'Bone marrow transplantation reverses metabolic alterations in multiple sulfatase deficiency: a case series.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Disease-causing homozygous or compound heterozygous variants in SUMF1 result in MSD."
    explanation: Human case-series background supports biallelic SUMF1 causation.
genetic:
- name: SUMF1
  association: Biallelic pathogenic variants
  presence: Positive
  gene_term:
    preferred_term: SUMF1
    term:
      id: hgnc:20376
      label: SUMF1
  notes: >-
    SUMF1 encodes formylglycine-generating enzyme, the ER protein required for
    post-translational activation of sulfatases. Pathogenic SUMF1 variants
    reduce FGE stability or activity, causing the multiple sulfatase deficiency
    phenotype.
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "SUMF1 | sulfatase modifying factor 1 | hgnc:20376 | Disease-causing germline mutation(s) in"
    explanation: Orphanet lists SUMF1 as the disease-causing gene.
  - reference: PMID:32414121
    reference_title: 'Multiple Sulfatase Deficiency: A Disease Comprising Mucopolysaccharidosis, Sphingolipidosis, and More Caused by a Defect in Posttranslational Modification.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MSD is caused by impaired posttranslational activation of sulfatases through the formylglycine generating enzyme (FGE) encoded by the sulfatase modifying factor 1 (SUMF1) gene, which is mutated in MSD."
    explanation: Review links SUMF1/FGE mutations to the biochemical defect.
  - reference: PMID:32620537
    reference_title: A systematic cross-sectional survey of multiple sulfatase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Multiple Sulfatase Deficiency (MSD) is an inborn error of metabolism caused by pathogenic variants in the SUMF1 gene encoding the formylglycine-generating enzyme (FGE) that activates all known sulfatases."
    explanation: Systematic clinical survey supports SUMF1 causation.
  - reference: CGGV:assertion_2d64d13d-c2dc-4749-8330-fade259ca381-2022-09-06T040000.000Z
    reference_title: "SUMF1 / mucosulfatidosis (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "SUMF1 | HGNC:20376 | mucosulfatidosis | MONDO:0010088 | AR | Definitive"
    explanation: ClinGen classifies the SUMF1-mucosulfatidosis gene-disease relationship as definitive with autosomal recessive inheritance.
pathophysiology:
- name: SUMF1 Formylglycine-Generating Enzyme Deficiency
  description: >-
    Pathogenic SUMF1 variants reduce formylglycine-generating enzyme stability
    or catalytic activity in the endoplasmic reticulum.
  genes:
  - preferred_term: SUMF1
    term:
      id: hgnc:20376
      label: SUMF1
  biological_processes:
  - preferred_term: post-translational sulfatase activation
    term:
      id: GO:0043687
      label: post-translational protein modification
    modifier: DECREASED
  locations:
  - preferred_term: endoplasmic reticulum
    term:
      id: GO:0005783
      label: endoplasmic reticulum
  evidence:
  - reference: PMID:12757705
    reference_title: Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C(alpha)-formylglycine generating enzyme.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "C(alpha)-formylglycine (FGly) is the catalytic residue in the active site of eukaryotic sulfatases."
    explanation: Cell/biochemical study establishes FGly as the active-site residue needed for sulfatase catalysis.
  - reference: PMID:12757705
    reference_title: Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C(alpha)-formylglycine generating enzyme.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We purified the FGly generating enzyme (FGE) and identified its gene and nine mutations in seven MSD patients."
    explanation: Study identified FGE and MSD patient mutations.
  - reference: PMID:32414121
    reference_title: 'Multiple Sulfatase Deficiency: A Disease Comprising Mucopolysaccharidosis, Sphingolipidosis, and More Caused by a Defect in Posttranslational Modification.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "SUMF1 mutations result in unstable, degradation-prone FGE that demonstrates reduced or absent catalytic activity, leading to decreased activity of all sulfatases."
    explanation: Review summarizes the variant-level FGE stability and activity defect.
  downstream:
  - target: Sulfatase Catalytic Activation Failure
    causal_link_type: DIRECT
    description: FGE deficiency prevents normal FGly-dependent activation of newly synthesized sulfatases.
- name: Sulfatase Catalytic Activation Failure
  description: >-
    Failed FGE-dependent formylglycine generation lowers activity of multiple
    cellular sulfatases, including lysosomal sulfatases.
  molecular_functions:
  - preferred_term: sulfatase activity
    term:
      id: GO:0008484
      label: sulfuric ester hydrolase activity
    modifier: DECREASED
  evidence:
  - reference: PMID:12757706
    reference_title: The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In multiple sulfatase deficiency (MSD), a human inherited disorder, the activities of all sulfatases are impaired due to a defect in posttranslational modification."
    explanation: Functional complementation paper directly states the shared sulfatase activity defect.
  - reference: PMID:12757706
    reference_title: The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Coexpression of SUMF1 with sulfatases results in a strikingly synergistic increase of enzymatic activity, indicating that SUMF1 is both an essential and a limiting factor for sulfatases."
    explanation: SUMF1 coexpression increases sulfatase activity, supporting causality.
  - reference: PMID:32414121
    reference_title: 'Multiple Sulfatase Deficiency: A Disease Comprising Mucopolysaccharidosis, Sphingolipidosis, and More Caused by a Defect in Posttranslational Modification.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "A complete loss of SUMF1 or FGE function results in decreased activity of all sulfatases rendering MSD a monogenetic disease"
    explanation: Review supports broad sulfatase activity reduction from SUMF1/FGE loss.
  downstream:
  - target: Reduced multiple sulfatase activities
    causal_link_type: DIRECT
    description: Failed FGly-dependent activation produces simultaneous deficiency of multiple sulfatase activities.
  - target: Sulfated Substrate Lysosomal Storage
    causal_link_type: DIRECT
    description: Decreased sulfatase activities impair degradation of glycosaminoglycans and sulfatides.
- name: Sulfated Substrate Lysosomal Storage
  description: >-
    Reduced sulfatase activities cause lysosomal accumulation of
    glycosaminoglycans, sulfatides, and other sulfated substrates.
  locations:
  - preferred_term: lysosome
    term:
      id: GO:0005764
      label: lysosome
  biological_processes:
  - preferred_term: lysosome organization
    term:
      id: GO:0007040
      label: lysosome organization
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:32414121
    reference_title: 'Multiple Sulfatase Deficiency: A Disease Comprising Mucopolysaccharidosis, Sphingolipidosis, and More Caused by a Defect in Posttranslational Modification.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "loss of sulfatase activity induces lysosomal storage of glycosaminoglycans and sulfatides and subsequent cellular pathology."
    explanation: Review links sulfatase loss to lysosomal storage.
  - reference: PMID:32620537
    reference_title: A systematic cross-sectional survey of multiple sulfatase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "FGE deficiency results in widespread tissue accumulation of multiple sulphated substrates."
    explanation: Systematic review supports tissue storage of sulfated substrates.
  downstream:
  - target: Glycosaminoglycan and sulfatide accumulation
    causal_link_type: DIRECT
  - target: Mucopolysacchariduria
    causal_link_type: DIRECT
    description: Impaired degradation of sulfated glycosaminoglycans leads to urinary mucopolysaccharide excretion.
  - target: Neuroglial Lysosomal Dysfunction
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - sulfated substrate storage in nervous-system cells
  - target: Retinal and Auditory Degeneration
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - sulfated substrate storage in sensory tissues
  - target: Skeletal and Joint Storage Manifestations
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - connective-tissue and skeletal storage pathology
  - target: Hepatomegaly
    causal_link_type: DIRECT
    description: Visceral lysosomal storage contributes to liver enlargement.
  - target: Splenomegaly
    causal_link_type: DIRECT
    description: Visceral lysosomal storage contributes to spleen enlargement.
  - target: Ichthyosis
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Sulfatase deficiency and sulfated lipid/substrate storage produce the ichthyotic skin phenotype.
  - target: Coarse hair
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Hair changes are grouped with cutaneous storage manifestations.
  - target: Coarse facial features
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Mucopolysaccharidosis-like storage produces coarse craniofacial features.
  - target: Smooth philtrum
    causal_link_type: UNKNOWN
    description: Smooth philtrum is retained as a craniofacial manifestation with unresolved proximal mechanism.
  - target: Anteverted nares
    causal_link_type: UNKNOWN
    description: Anteverted nares is retained as a craniofacial manifestation with unresolved proximal mechanism.
  - target: Thick eyebrow
    causal_link_type: UNKNOWN
    description: Thick eyebrows are grouped with coarse craniofacial and hair manifestations.
  - target: Depressed nasal bridge
    causal_link_type: UNKNOWN
    description: Depressed nasal bridge is retained as a craniofacial manifestation with unresolved proximal mechanism.
- name: Neuroglial Lysosomal Dysfunction
  description: >-
    Sulfatide and glycosaminoglycan storage in neurons and glia — particularly
    astrocytes — impairs lysosomal and autophagic function, compromising the
    cellular processes that maintain nervous-system homeostasis.
  locations:
  - preferred_term: lysosome
    term:
      id: GO:0005764
      label: lysosome
  cell_types:
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: autophagy
    term:
      id: GO:0006914
      label: autophagy
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:32414121
    reference_title: 'Multiple Sulfatase Deficiency: A Disease Comprising Mucopolysaccharidosis, Sphingolipidosis, and More Caused by a Defect in Posttranslational Modification.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "This abnormal storage results in lysosomal dysfunction, impacting several cellular processes including autophagy"
    explanation: Review supports lysosomal and autophagic dysfunction downstream of sulfated-substrate storage.
  - reference: PMID:32414121
    reference_title: 'Multiple Sulfatase Deficiency: A Disease Comprising Mucopolysaccharidosis, Sphingolipidosis, and More Caused by a Defect in Posttranslational Modification.'
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Astrocyte specific knock-out of SUMF1 in a Cre/Lox MSD mouse model revealed lysosomal storage of substrates and autophagy substrates impairing astrocyte function."
    explanation: Model-organism evidence connects SUMF1 loss to lysosomal storage and impaired astrocyte function.
  downstream:
  - target: Neurodegeneration
    causal_link_type: DIRECT
    description: Astrocyte and neuroglial dysfunction drives progressive neuronal loss.
- name: Neurodegeneration
  description: >-
    Neuroglial dysfunction produces progressive neuronal loss and central and
    peripheral nervous-system degeneration, manifesting as leukodystrophy-like
    disease, developmental impairment, regression, seizures, and peripheral
    nerve involvement.
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  evidence:
  - reference: PMID:32414121
    reference_title: 'Multiple Sulfatase Deficiency: A Disease Comprising Mucopolysaccharidosis, Sphingolipidosis, and More Caused by a Defect in Posttranslational Modification.'
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "impairing astrocyte function. This led to neuronal loss thereby highlighting the importance of astrocyte dysfunction in the pathophysiology of MSD"
    explanation: Model-organism evidence shows astrocyte dysfunction leads to neuronal loss in MSD.
  - reference: PMID:32620537
    reference_title: A systematic cross-sectional survey of multiple sulfatase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MSD is an ultra-rare multisystem disorder with mainly neurologic, hearing and skin involvements."
    explanation: Systematic clinical survey supports neurologic involvement as a main disease domain.
  downstream:
  - target: Hydrocephalus
    causal_link_type: UNKNOWN
    description: Hydrocephalus is connected through central nervous system involvement, but the proximal mechanism is not separately modeled.
  - target: Leukodystrophy
    causal_link_type: DIRECT
  - target: Microcephaly
    causal_link_type: UNKNOWN
    description: Microcephaly is modeled as a CNS growth/development manifestation of severe neurodevelopmental disease.
  - target: Macrocephaly
    causal_link_type: UNKNOWN
    description: Macrocephaly is modeled as a CNS growth or hydrocephalus-related manifestation with unresolved proximal mechanism.
  - target: Intellectual disability
    causal_link_type: DIRECT
  - target: Seizure
    causal_link_type: DIRECT
  - target: Global developmental delay
    causal_link_type: DIRECT
  - target: Neonatal hypotonia
    causal_link_type: DIRECT
  - target: Developmental regression
    causal_link_type: DIRECT
  - target: Abnormality of peripheral nerve conduction
    causal_link_type: DIRECT
  - target: Rapid neurologic deterioration
    causal_link_type: DIRECT
- name: Retinal and Auditory Degeneration
  description: >-
    MSD commonly affects sensory systems through retinal degeneration and
    sensorineural hearing impairment.
  evidence:
  - reference: PMID:36980153
    reference_title: Multiple Sulfatase Deficiency from an Ophthalmologist's Perspective-Case Report and Literature Review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In 50-75% of all MSD-affected patients, functional or structural ocular damage is likely."
    explanation: Ophthalmology review supports common ocular damage.
  - reference: PMID:36980153
    reference_title: Multiple Sulfatase Deficiency from an Ophthalmologist's Perspective-Case Report and Literature Review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The main pathology these patients present is a highly conspicuous tapetoretinal degeneration, similar to severe Retinitis pigmentosa, that leads to blindness at an early age."
    explanation: Review identifies tapetoretinal degeneration as the main ocular pathology.
  - reference: PMID:32620537
    reference_title: A systematic cross-sectional survey of multiple sulfatase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Leukodystrophy, neurosensorial hearing loss, and ichthyosis were the most frequent findings at diagnosis."
    explanation: Systematic review supports hearing loss as a frequent diagnostic finding.
  downstream:
  - target: Sensorineural hearing impairment
    causal_link_type: DIRECT
  - target: Visual impairment
    causal_link_type: DIRECT
  - target: Cataract
    causal_link_type: UNKNOWN
    description: Cataract is modeled as an ocular manifestation of MSD, with the proximal tissue mechanism not separately curated.
  - target: Optic atrophy
    causal_link_type: DIRECT
  - target: Abnormality of retinal pigmentation
    causal_link_type: DIRECT
  - target: Corneal opacity
    causal_link_type: UNKNOWN
    description: Corneal opacity is modeled as an ocular storage manifestation with unresolved proximal mechanism.
- name: Skeletal and Joint Storage Manifestations
  description: >-
    Mucopolysaccharidosis-like connective-tissue and skeletal storage pathology
    causes short stature, joint stiffness, and broad distal phalanges.
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "skeletal anomalies"
    explanation: Orphanet definition includes skeletal anomalies among MSD manifestations.
  - reference: PMID:32414121
    reference_title: 'Multiple Sulfatase Deficiency: A Disease Comprising Mucopolysaccharidosis, Sphingolipidosis, and More Caused by a Defect in Posttranslational Modification.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Many individuals also have characteristic facial features consistent with MPS disorders, chondrodysplasia punctata, hepatosplenomegaly, and ichthyosis"
    explanation: Review supports MPS-like skeletal/connective-tissue involvement.
  downstream:
  - target: Joint stiffness
    causal_link_type: DIRECT
  - target: Short stature
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Skeletal storage and dysplasia contribute to impaired linear growth.
  - target: Broad hallux phalanx
    causal_link_type: DIRECT
  - target: Broad thumb
    causal_link_type: DIRECT
phenotypes:
- category: Neurologic
  name: Hydrocephalus
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Hydrocephalus
    term:
      id: HP:0000238
      label: Hydrocephalus
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000238 | Hydrocephalus | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- category: Neurologic
  name: Leukodystrophy
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Leukodystrophy
    term:
      id: HP:0002415
      label: Leukodystrophy
  evidence:
  - reference: PMID:32620537
    reference_title: A systematic cross-sectional survey of multiple sulfatase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Leukodystrophy, neurosensorial hearing loss, and ichthyosis were the most frequent findings at diagnosis."
    explanation: Systematic review supports leukodystrophy as one of the most frequent findings at diagnosis.
- category: Neurologic
  name: Microcephaly
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Microcephaly
    term:
      id: HP:0000252
      label: Microcephaly
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000252 | Microcephaly | Occasional (29-5%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- category: Neurologic
  name: Macrocephaly
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Macrocephaly
    term:
      id: HP:0000256
      label: Macrocephaly
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000256 | Macrocephaly | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- category: Craniofacial
  name: Coarse facial features
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Coarse facial features
    term:
      id: HP:0000280
      label: Coarse facial features
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000280 | Coarse facial features | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- category: Craniofacial
  name: Smooth philtrum
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Smooth philtrum
    term:
      id: HP:0000319
      label: Smooth philtrum
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000319 | Smooth philtrum | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- category: Auditory
  name: Sensorineural hearing impairment
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000407 | Sensorineural hearing impairment | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
  - reference: PMID:32620537
    reference_title: A systematic cross-sectional survey of multiple sulfatase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Leukodystrophy, neurosensorial hearing loss, and ichthyosis were the most frequent findings at diagnosis."
    explanation: Systematic review supports hearing loss as a frequent finding at diagnosis.
- category: Craniofacial
  name: Anteverted nares
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Anteverted nares
    term:
      id: HP:0000463
      label: Anteverted nares
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000463 | Anteverted nares | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- category: Ophthalmologic
  name: Visual impairment
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Visual impairment
    term:
      id: HP:0000505
      label: Visual impairment
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000505 | Visual impairment | Very frequent (99-80%)"
    explanation: Orphanet provides the phenotype association and frequency band.
  - reference: PMID:36980153
    reference_title: Multiple Sulfatase Deficiency from an Ophthalmologist's Perspective-Case Report and Literature Review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In 50-75% of all MSD-affected patients, functional or structural ocular damage is likely."
    explanation: Ophthalmology review supports common ocular involvement.
- category: Ophthalmologic
  name: Cataract
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Cataract
    term:
      id: HP:0000518
      label: Cataract
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000518 | Cataract | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- category: Craniofacial
  name: Thick eyebrow
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Thick eyebrow
    term:
      id: HP:0000574
      label: Thick eyebrow
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000574 | Thick eyebrow | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- category: Ophthalmologic
  name: Optic atrophy
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Optic atrophy
    term:
      id: HP:0000648
      label: Optic atrophy
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000648 | Optic atrophy | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- category: Neurologic
  name: Intellectual disability
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001249 | Intellectual disability | Very frequent (99-80%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- category: Neurologic
  name: Seizure
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001250 | Seizure | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- category: Neurologic
  name: Global developmental delay
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001263 | Global developmental delay | Very frequent (99-80%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- category: Neurologic
  name: Neonatal hypotonia
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Neonatal hypotonia
    term:
      id: HP:0001319
      label: Neonatal hypotonia
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001319 | Neonatal hypotonia | Very frequent (99-80%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- category: Musculoskeletal
  name: Joint stiffness
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Joint stiffness
    term:
      id: HP:0001387
      label: Joint stiffness
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001387 | Joint stiffness | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- category: Visceral
  name: Splenomegaly
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Splenomegaly
    term:
      id: HP:0001744
      label: Splenomegaly
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001744 | Splenomegaly | Very frequent (99-80%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- category: Integument
  name: Coarse hair
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Coarse hair
    term:
      id: HP:0002208
      label: Coarse hair
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002208 | Coarse hair | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- category: Visceral
  name: Hepatomegaly
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Hepatomegaly
    term:
      id: HP:0002240
      label: Hepatomegaly
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002240 | Hepatomegaly | Very frequent (99-80%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- category: Neurologic
  name: Developmental regression
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Developmental regression
    term:
      id: HP:0002376
      label: Developmental regression
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002376 | Developmental regression | Very frequent (99-80%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- category: Neurologic
  name: Abnormality of peripheral nerve conduction
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Abnormality of peripheral nerve conduction
    term:
      id: HP:0003134
      label: Abnormality of peripheral nerve conduction
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0003134 | Abnormality of peripheral nerve conduction | Very frequent (99-80%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- category: Growth
  name: Short stature
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0004322 | Short stature | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- category: Craniofacial
  name: Depressed nasal bridge
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Depressed nasal bridge
    term:
      id: HP:0005280
      label: Depressed nasal bridge
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0005280 | Depressed nasal bridge | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- category: Neurologic
  name: Rapid neurologic deterioration
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Rapid neurologic deterioration
    term:
      id: HP:0007307
      label: Rapid neurologic deterioration
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0007307 | Rapid neurologic deterioration | Very frequent (99-80%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- category: Ophthalmologic
  name: Abnormality of retinal pigmentation
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Abnormality of retinal pigmentation
    term:
      id: HP:0007703
      label: Abnormal retinal pigmentation
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0007703 | Abnormality of retinal pigmentation | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
  - reference: PMID:36980153
    reference_title: Multiple Sulfatase Deficiency from an Ophthalmologist's Perspective-Case Report and Literature Review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The main pathology these patients present is a highly conspicuous tapetoretinal degeneration, similar to severe Retinitis pigmentosa, that leads to blindness at an early age."
    explanation: Ophthalmology review supports retinal pigmentary degeneration as a major ocular manifestation.
- category: Ophthalmologic
  name: Corneal opacity
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Corneal opacity
    term:
      id: HP:0007957
      label: Corneal opacity
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0007957 | Corneal opacity | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- category: Integument
  name: Ichthyosis
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Ichthyosis
    term:
      id: HP:0008064
      label: Ichthyosis
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0008064 | Ichthyosis | Very frequent (99-80%)"
    explanation: Orphanet provides the phenotype association and frequency band.
  - reference: PMID:32620537
    reference_title: A systematic cross-sectional survey of multiple sulfatase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Leukodystrophy, neurosensorial hearing loss, and ichthyosis were the most frequent findings at diagnosis."
    explanation: Systematic review supports ichthyosis as a frequent diagnostic finding.
- category: Biochemical
  name: Mucopolysacchariduria
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Mucopolysacchariduria
    term:
      id: HP:0008155
      label: Mucopolysacchariduria
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0008155 | Mucopolysacchariduria | Very frequent (99-80%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- category: Musculoskeletal
  name: Broad hallux phalanx
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Broad hallux phalanx
    term:
      id: HP:0010059
      label: Broad hallux phalanx
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0010059 | Broad hallux phalanx | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
- category: Musculoskeletal
  name: Broad thumb
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Broad thumb
    term:
      id: HP:0011304
      label: Broad thumb
  evidence:
  - reference: ORPHA:585
    reference_title: Multiple sulfatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0011304 | Broad thumb | Frequent (79-30%)"
    explanation: Orphanet provides the phenotype association and frequency band.
biochemical:
- name: Reduced multiple sulfatase activities
  presence: Deficient
  notes: >-
    Diagnostic biochemical testing demonstrates simultaneous reduction of
    multiple sulfatase activities, typically measured in leukocytes or
    fibroblasts.
  evidence:
  - reference: PMID:32414121
    reference_title: 'Multiple Sulfatase Deficiency: A Disease Comprising Mucopolysaccharidosis, Sphingolipidosis, and More Caused by a Defect in Posttranslational Modification.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Historically, the clinical diagnosis of MSD was confirmed by measuring simultaneous deficiency of more than one sulfatase activity in patient leukocytes or fibroblasts."
    explanation: Review supports simultaneous low sulfatase activity as a diagnostic biochemical finding.
  - reference: PMID:29397290
    reference_title: 'Complex care of individuals with multiple sulfatase deficiency: Clinical cases and consensus statement.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "When FGE is absent or insufficient, all 17 known human sulfatases are affected"
    explanation: Consensus statement supports broad sulfatase involvement.
- name: Glycosaminoglycan and sulfatide accumulation
  presence: Positive
  notes: >-
    Sulfatase deficiency causes accumulation of sulfated substrates including
    glycosaminoglycans and sulfatides.
  evidence:
  - reference: PMID:32414121
    reference_title: 'Multiple Sulfatase Deficiency: A Disease Comprising Mucopolysaccharidosis, Sphingolipidosis, and More Caused by a Defect in Posttranslational Modification.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "loss of sulfatase activity induces lysosomal storage of glycosaminoglycans and sulfatides and subsequent cellular pathology."
    explanation: Review supports storage of glycosaminoglycans and sulfatides.
  - reference: PMID:32620537
    reference_title: A systematic cross-sectional survey of multiple sulfatase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "FGE deficiency results in widespread tissue accumulation of multiple sulphated substrates."
    explanation: Systematic review supports widespread accumulation of sulfated substrates.
histopathology:
- name: Pleomorphic lysosomal inclusions
  description: >-
    Tissue pathology can show pleomorphic lysosomal inclusions in peripheral
    nerve Schwann cells and brain tissue, consistent with multisubstrate
    lysosomal storage.
  evidence:
  - reference: PMID:32414121
    reference_title: 'Multiple Sulfatase Deficiency: A Disease Comprising Mucopolysaccharidosis, Sphingolipidosis, and More Caused by a Defect in Posttranslational Modification.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Ultrastructural findings comprise pleomorphic lysosomal inclusions in Schwann cells detected in skin biopsies"
    explanation: Review summarizes reported ultrastructural storage pathology.
diagnosis:
- name: Multiple sulfatase enzyme activity testing
  description: >-
    Measurement of several sulfatase activities in leukocytes or fibroblasts is
    the key biochemical diagnostic test; at least three sulfatases should be
    measured to reduce false-negative risk.
  evidence:
  - reference: PMID:32414121
    reference_title: 'Multiple Sulfatase Deficiency: A Disease Comprising Mucopolysaccharidosis, Sphingolipidosis, and More Caused by a Defect in Posttranslational Modification.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Given these diagnostic challenges, we recommend a combination of genetic and biochemical testing with the measurement of at least three sulfatases."
    explanation: Review recommends combined genetic and biochemical testing with multiple sulfatase measurements.
  - reference: PMID:32414121
    reference_title: 'Multiple Sulfatase Deficiency: A Disease Comprising Mucopolysaccharidosis, Sphingolipidosis, and More Caused by a Defect in Posttranslational Modification.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The diagnosis of MSD is based on reduced sulfatase activities and detection of mutations in SUMF1."
    explanation: Review summarizes diagnostic basis.
- name: SUMF1 molecular genetic testing
  description: >-
    Molecular testing confirms biallelic pathogenic SUMF1 variants and helps
    distinguish MSD from single sulfatase deficiencies or pseudodeficiency.
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: MAXO:0000127
      label: genetic testing
  evidence:
  - reference: PMID:32414121
    reference_title: 'Multiple Sulfatase Deficiency: A Disease Comprising Mucopolysaccharidosis, Sphingolipidosis, and More Caused by a Defect in Posttranslational Modification.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Nowadays, SUMF1 genetic testing supports the diagnosis of MSD."
    explanation: Review supports SUMF1 genetic testing for diagnosis.
  - reference: PMID:39789203
    reference_title: 'Bone marrow transplantation reverses metabolic alterations in multiple sulfatase deficiency: a case series.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Disease-causing homozygous or compound heterozygous variants in SUMF1 result in MSD."
    explanation: Case-series background supports pathogenic biallelic SUMF1 variants.
- name: Urinary glycosaminoglycan and sulfatide screening
  description: >-
    Urinary glycosaminoglycan and sulfatide testing can support suspicion, but
    negative glycosaminoglycan results do not exclude MSD.
  evidence:
  - reference: PMID:32414121
    reference_title: 'Multiple Sulfatase Deficiency: A Disease Comprising Mucopolysaccharidosis, Sphingolipidosis, and More Caused by a Defect in Posttranslational Modification.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The simultaneous excretion of heparan sulfate, dermatan sulfate, keratan sulfate and chondroitin sulfate is strongly suggestive of MSD."
    explanation: Review supports urine glycosaminoglycan screening as suggestive.
  - reference: PMID:32414121
    reference_title: 'Multiple Sulfatase Deficiency: A Disease Comprising Mucopolysaccharidosis, Sphingolipidosis, and More Caused by a Defect in Posttranslational Modification.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Interestingly, increased GAG excretion is absent in some MSD patients"
    explanation: Review notes false-negative risk for GAG excretion testing.
treatments:
- name: Multidisciplinary palliative and supportive care
  description: >-
    No curative therapy is established; management is individualized and
    multidisciplinary, addressing neurologic, respiratory, feeding,
    musculoskeletal, ocular, auditory, dermatologic, visceral, and family
    quality-of-life needs.
  treatment_term:
    preferred_term: palliative care
    term:
      id: MAXO:0000021
      label: palliative care
  evidence:
  - reference: PMID:32414121
    reference_title: 'Multiple Sulfatase Deficiency: A Disease Comprising Mucopolysaccharidosis, Sphingolipidosis, and More Caused by a Defect in Posttranslational Modification.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "No curative therapy is currently available for MSD."
    explanation: Review states that established curative therapy is unavailable.
  - reference: PMID:32414121
    reference_title: 'Multiple Sulfatase Deficiency: A Disease Comprising Mucopolysaccharidosis, Sphingolipidosis, and More Caused by a Defect in Posttranslational Modification.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "An expert-driven multidisciplinary approach with goal of a high quality-of-life for the affected individuals and also the care-givers should be the primary objective of care"
    explanation: Review supports multidisciplinary quality-of-life-centered care.
  - reference: PMID:29397290
    reference_title: 'Complex care of individuals with multiple sulfatase deficiency: Clinical cases and consensus statement.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "we detail a comprehensive systems-based approach to the management of individuals with MSD, from the initial diagnostic evaluation to unique multisystem issues and potential management options."
    explanation: Consensus statement supports systems-based complex management.
- name: Hematopoietic cell transplantation
  description: >-
    Hematopoietic cell or bone marrow transplantation is investigational in MSD;
    a two-sibling attenuated-MSD case series reports correction of available
    biomarkers and possible slowing of disease progression, with longer
    follow-up needed.
  treatment_term:
    preferred_term: bone marrow transplantation
    term:
      id: MAXO:0010030
      label: bone marrow transplantation
  target_mechanisms:
  - target: Sulfated Substrate Lysosomal Storage
    treatment_effect: MODULATES
    description: Donor-derived hematopoietic cells may provide lysosomal enzymatic cross-correction.
    evidence:
    - reference: PMID:39789203
      reference_title: 'Bone marrow transplantation reverses metabolic alterations in multiple sulfatase deficiency: a case series.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Two siblings with attenuated MSD underwent hematopoietic cell transplantation (HCT), evaluating the possibility of lysosomal enzymatic cross-correction from the donor cells."
      explanation: Human case series states the proposed cross-correction rationale for HCT.
  evidence:
  - reference: PMID:39789203
    reference_title: 'Bone marrow transplantation reverses metabolic alterations in multiple sulfatase deficiency: a case series.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There is evidence of correction of currently available biomarkers within 3 months post-HCT."
    explanation: Case series supports biochemical correction after HCT.
  - reference: PMID:39789203
    reference_title: 'Bone marrow transplantation reverses metabolic alterations in multiple sulfatase deficiency: a case series.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These data suggest biochemical benefits post-transplant along with slowing of disease progression."
    explanation: Case series supports possible clinical benefit while acknowledging need for longer follow-up.
- name: AAV9-SUMF1 gene replacement therapy
  description: >-
    AAV9/SUMF1 gene replacement is a preclinical strategy designed to supply
    functional SUMF1 and restore sulfatase activity; evidence is currently from
    mouse and rat preclinical studies rather than clinical use.
  treatment_term:
    preferred_term: gene therapy
    term:
      id: MAXO:0001001
      label: gene therapy
  target_mechanisms:
  - target: SUMF1 Formylglycine-Generating Enzyme Deficiency
    treatment_effect: RESTORES
    description: Gene replacement delivers functional SUMF1 coding sequence.
    evidence:
    - reference: PMID:39870870
      reference_title: Preclinical use of a clinically-relevant scAAV9/SUMF1 vector for the treatment of multiple sulfatase deficiency.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "We engineered a viral vector (AAV9/SUMF1) to deliver working copies of the SUMF1 gene and tested the vector in Sumf1 knock out mice"
      explanation: Preclinical study describes AAV9/SUMF1 gene delivery in a mouse model.
  - target: Sulfatase Catalytic Activation Failure
    treatment_effect: RESTORES
    description: Functional SUMF1 restores FGE-dependent sulfatase activation.
    evidence:
    - reference: PMID:39870870
      reference_title: Preclinical use of a clinically-relevant scAAV9/SUMF1 vector for the treatment of multiple sulfatase deficiency.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "One-year post treatment, tissues show increased sulfatase activity, indicating functional SUMF1."
      explanation: Preclinical study reports increased sulfatase activity after AAV9/SUMF1 treatment.
  evidence:
  - reference: PMID:39870870
    reference_title: Preclinical use of a clinically-relevant scAAV9/SUMF1 vector for the treatment of multiple sulfatase deficiency.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "treatment of neonates extends survival up to 1-year post-injection."
    explanation: Mouse study supports survival extension after neonatal AAV9/SUMF1 treatment.
  - reference: PMID:39870870
    reference_title: Preclinical use of a clinically-relevant scAAV9/SUMF1 vector for the treatment of multiple sulfatase deficiency.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The treated mice show wide distribution of the SUMF1 gene, no signs of toxicity or neuropathy, improved vision and cardiac function, and no behavioral deficits."
    explanation: Preclinical study supports broad distribution and phenotypic improvements.
clinical_trials: []
notes: >-
  MSD combines features of several single sulfatase deficiencies because FGE is
  required for activation of all known cellular sulfatases. HCT and AAV9/SUMF1
  are represented as emerging or investigational strategies, not as established
  curative clinical therapies.
📚

References & Deep Research

References

9
ORPHA:585
Multiple sulfatase deficiency
1 finding
Orphanet defines multiple sulfatase deficiency as a rare lysosomal disease combining features of several sulfatase deficiencies, with severe to attenuated neonatal, infantile, and juvenile forms.
"A rare lysosomal disease characterized by a clinical phenotype that combines the features of different sulfatase deficiencies (whether lysosomal or not)."
PMID:32414121
Multiple Sulfatase Deficiency: A Disease Comprising Mucopolysaccharidosis, Sphingolipidosis, and More Caused by a Defect in Posttranslational Modification.
1 finding
Review evidence supports SUMF1/FGE deficiency, impaired sulfatase post-translational activation, decreased sulfatase activity, lysosomal glycosaminoglycan and sulfatide storage, diagnosis by sulfatase activity and SUMF1 testing, and lack of curative therapy.
"MSD is caused by impaired posttranslational activation of sulfatases through the formylglycine generating enzyme (FGE) encoded by the sulfatase modifying factor 1 (SUMF1) gene."
PMID:32620537
A systematic cross-sectional survey of multiple sulfatase deficiency.
1 finding
A systematic review of 80 published MSD cases supports SUMF1 causation, widespread sulphated substrate accumulation, common leukodystrophy, hearing loss, ichthyosis, prevalence estimates, and worse survival in neonatal-onset disease.
"Through a systematic analysis of published cases, we retrieved 80 MSD cases and reviewed the disease clinical, biochemical, and genetic findings."
PMID:12757705
Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C(alpha)-formylglycine generating enzyme.
1 finding
The original FGE discovery paper identified FGE/SUMF1 and MSD patient mutations, showed FGly formation as the common sulfatase activation step, and restored sulfatase activity in patient fibroblasts by FGE cDNA.
"We purified the FGly generating enzyme (FGE) and identified its gene and nine mutations in seven MSD patients."
PMID:12757706
The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases.
1 finding
Functional complementation identified the MSD gene, rescued patient-cell sulfatase deficiency, and showed SUMF1 is essential and limiting for sulfatase activity.
"Coexpression of SUMF1 with sulfatases results in a strikingly synergistic increase of enzymatic activity, indicating that SUMF1 is both an essential and a limiting factor for sulfatases."
PMID:29397290
Complex care of individuals with multiple sulfatase deficiency: Clinical cases and consensus statement.
1 finding
Consensus evidence supports the multisystem clinical phenotype and a systems-based complex-care approach for diagnostic evaluation and management.
"we detail a comprehensive systems-based approach to the management of individuals with MSD, from the initial diagnostic evaluation to unique multisystem issues and potential management options."
PMID:36980153
Multiple Sulfatase Deficiency from an Ophthalmologist's Perspective-Case Report and Literature Review.
1 finding
Ophthalmology-focused review supports frequent ocular involvement, tapetoretinal degeneration, and progressive visual loss in MSD.
"In 50-75% of all MSD-affected patients, functional or structural ocular damage is likely."
PMID:39789203
Bone marrow transplantation reverses metabolic alterations in multiple sulfatase deficiency: a case series.
1 finding
A 2025 human case series reports biochemical correction and possible slowing of progression after hematopoietic cell transplantation in two siblings with attenuated MSD.
"These data suggest biochemical benefits post-transplant along with slowing of disease progression."
PMID:39870870
Preclinical use of a clinically-relevant scAAV9/SUMF1 vector for the treatment of multiple sulfatase deficiency.
1 finding
A 2025 preclinical study supports AAV9/SUMF1 gene replacement in a mouse model, with survival extension, improved symptoms, and increased sulfatase activity.
"These preclinical studies highlight the potential of our AAV9/SUMF1 vector, the design of which is directly translatable for clinical use, as a gene replacement therapy for MSD patients."

Deep Research

1
Multiple sulfatase deficiency research fallback ▸

Multiple sulfatase deficiency research fallback

Provider attempts

  • Falcon deep-research: initial call before YAML creation failed because the target disorder file did not yet exist; a bounded retry after YAML creation timed out after 75 seconds without producing an artifact.
  • OpenAI deep-research: bounded attempt after YAML creation timed out after 75 seconds without producing an artifact.
  • Perplexity deep-research: skipped after bounded Falcon/OpenAI failures; curation proceeded from generated Orphanet, PubMed, and full-text caches.

Literature scope used for curation

This fallback curation uses generated reference caches for ORPHA:585, primary SUMF1/FGE mechanism papers (PMID:12757705, PMID:12757706), a full-text MSD mechanism/clinical review (PMID:32414121), a systematic 80-case survey (PMID:32620537), a complex-care consensus statement (PMID:29397290), an ophthalmology literature review (PMID:36980153), a 2025 HCT case series (PMID:39789203), and a 2025 preclinical AAV9/SUMF1 study (PMID:39870870).

Curation synthesis

Multiple sulfatase deficiency is caused by biallelic SUMF1 variants affecting formylglycine-generating enzyme, an ER protein required to activate cellular sulfatases through post-translational FGly generation. Loss of FGE function reduces multiple sulfatase activities, causing glycosaminoglycan and sulfatide lysosomal storage, neurodegeneration, sensory involvement, ichthyosis, hepatosplenomegaly, skeletal manifestations, and characteristic biochemical findings. Established management is multidisciplinary and palliative/supportive; HCT has limited human case-series evidence and AAV9/SUMF1 has preclinical model-organism evidence.

Key references

  • ORPHA:585
  • PMID:32414121
  • PMID:32620537
  • PMID:12757705
  • PMID:12757706
  • PMID:29397290
  • PMID:36980153
  • PMID:39789203
  • PMID:39870870